KBKatie T. Blissit

Katie T. Blissit

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Katie T. Blissit has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Christine Latham

    Katie T. Blissit, Pharm.D., is Postgraduate Year 1 Pharmacy Resident, William Jennings Bryan Dorn Veterans Affairs Medical Center, Columbia, SC. Erika Tillery, Pharm.D., is Clinical Pharmacist and Assistant Professor of Pharmacy Practice, School of Pharmacy, South University, Columbia. Christine Latham, B.S.Pharm., is Director of Pharmacy Services; and Jimmy Pacheco-Perez, M.D., is Chief Psychiatrist, G. Werber Bryan Psychiatric Hospital, Columbia

    1 shared publication
  • Erika Tillery

    Katie T. Blissit, Pharm.D., is Postgraduate Year 1 Pharmacy Resident, William Jennings Bryan Dorn Veterans Affairs Medical Center, Columbia, SC. Erika Tillery, Pharm.D., is Clinical Pharmacist and Assistant Professor of Pharmacy Practice, School of Pharmacy, South University, Columbia. Christine Latham, B.S.Pharm., is Director of Pharmacy Services; and Jimmy Pacheco-Perez, M.D., is Chief Psychiatrist, G. Werber Bryan Psychiatric Hospital, Columbia

    1 shared publication
  • Jimmy Pacheco-Perez

    Katie T. Blissit, Pharm.D., is Postgraduate Year 1 Pharmacy Resident, William Jennings Bryan Dorn Veterans Affairs Medical Center, Columbia, SC. Erika Tillery, Pharm.D., is Clinical Pharmacist and Assistant Professor of Pharmacy Practice, School of Pharmacy, South University, Columbia. Christine Latham, B.S.Pharm., is Director of Pharmacy Services; and Jimmy Pacheco-Perez, M.D., is Chief Psychiatrist, G. Werber Bryan Psychiatric Hospital, Columbia

    1 shared publication
  • Kevin G. Brittain

    William Jennings Bryan Dorn VA Medical Center, Columbia, SC, USA

    1 shared publication
  • Mackenzie L. Mullenix

    Kaiser Permanente Georgia, Southwood Medical Center, Jonesboro, GA, USA

    1 shared publication

Latest Publications

  • Evaluation of Time in Therapeutic Range on Warfarin Therapy Between Face-to-Face and Telephone Follow-Up in a VA Medical Center

    by Katie T. Blissit, Mackenzie L. Mullenix, Kevin G. Brittain

    Background: Few studies have evaluated percent time in therapeutic range (TTR) for warfarin managed via face-to-face (FF) to telephone (TELE) visits—all finding no difference between groups. Objective: Compare and evaluate TTR for warfarin in patients who received pharmacist-managed care via FF or TELE. Methods: Single-center, retrospective study. Eligible participants were ≥18 years old, on indefinite warfarin therapy, followed by clinical pharmacists via FF or TELE from 2010 to 2012. Primary outcome (TTR) calculated via Rosendaal method. Event data included rates of any bleeding, significant bleeding, deep vein thrombosis, pulmonary embolism, cerebrovascular accident, hospitalizations, and death. Clinics were also compared by location. Results: Two hundred subjects (90 FF and 110 TELE) were included. Mean TTR was 68.17% and 69.57% in FF and TELE groups, respectively. The FF group had statistically significant higher rates of any bleeding (48.9% vs 30.9%). Rates of significant bleeding in FF versus TELE were not significantly different (6.67% vs 2.73%). The majority followed FF with significant bleeding were at a higher bleeding risk than those followed via TELE. There were low rates of venous thromboembolism (1.1% and 1.8%). Conclusions: TTR was ≥65% for most subjects with minimal variability in TTR between clinics. Mean TTR results for each group were greater and above the threshold that has been commonly described in the literature as quality control, suggesting a progression in implementation of telephone-based anticoagulation management.


  • Glycopyrrolate for treatment of clozapine-induced sialorrhea in adults

    by Katie T. Blissit, Erika Tillery, Christine Latham, Jimmy Pacheco-Perez

    Four cases in which glycopyrrolate was used to treat clozapine-induced sialorrhea (CIS) are reported. Glycopyrrolate is an antimuscarinic agent that can be used preoperatively to inhibit drooling and excessive secretions of the respiratory tract. The outcomes of four patients who received glycopyrrolate for the treatment of CIS are described. The Thomas-Stonell and Greenberg Drooling Severity and Frequency Scale (DSFS) was used retrospectively to rate patients' drooling. Glycopyrrolate was effective in alleviating CIS in cases 1-3. Two patients (cases 1 and 4) exhibited severe drooling, which caused their clothing, hands, and objects to consistently become wet. One patient (case 1) responded well to glycopyrrolate and was restarted on the medication when CIS returned after discontinuation of the drug. While another patient (case 3) displayed a similar response to therapy for CIS as the patient described in case 1, this patient did not experience the psychosocial complications as did the patient in case 1, possibly due to the use of glycopyrrolate as the initial treatment of choice. The patient in case 2 experienced moderate but frequent drooling. Thioridazine's high anticholinergic potential may have contributed to this patient's lower baseline DSFS score compared with the scores of the other three patients, or it could have augmented initial symptom improvement. CIS continued in the patient described in case 4 despite treatment with glycopyrrolate, with only mild improvement in the severity and frequency of drooling. Glycopyrrolate was effective in alleviating symptoms in three of four patients with CIS. In a fourth patient, the degree of improvement was unknown due to documentation discrepancies; however, mild improvement was noted initially.